Clover Health Investments, Corp.

As of June 30, 2026, Clover Health Investments Corp. Class A carries a market capitalization of 2.43B, placing it among publicly traded companies globally. Its enterprise value stands at 2.22B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Clover Health Investments Corp. Class A's next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Clover Health Investments Corp. Class A has 529.15M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.10, and the price-to-book ratio stands at 7.39.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.02 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.22B versus a market cap of 2.43B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Clover Health Investments Corp. Class A maintains a current ratio of 1.50, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Clover Health Investments Corp. Class A posted a negative return on equity (ROE) of -5.10, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.84, reflecting losses generated across the asset base. The company generates approximately 3.16M in revenue per employee across its workforce of 685.50, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Clover Health Investments Corp. Class A's stock has gained approximately 59.07% over the past 52 weeks. The 50-day moving average sits at 3.91, while the 200-day moving average is 3.06.

Over the twelve months ended June 30, 2026, Clover Health Investments Corp. Class A generated 2.17B in revenue and converted that into -16.07M in net income, yielding earnings per share of -0.03. EBITDA reached -14.40M, while operating income came in at -16.07M.

These figures are as of June 30, 2026. Total book value stands at 329.34M, with working capital of 141.90M providing operational flexibility.

Clover Health Investments Corp. Class A produced 67.43M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.47M in capital expenditures, free cash flow totaled 64.96M - equivalent to 0.13 per share.

Over the twelve months ended June 30, 2026, Clover Health Investments Corp. Class A posted a gross margin of 18.57, reflecting its pricing power and cost economics. The operating margin of -0.74 and net profit margin of -0.74 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 2.68, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.77, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Clover Health Investments Corp. Class A shareholders.

As of June 30, 2026, Clover Health Investments Corp. Class A has an Altman Z-Score of 4.13, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.